BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 18639646)

  • 1. Progress in the evaluation of CDK inhibitors as anti-tumor agents.
    McInnes C
    Drug Discov Today; 2008 Oct; 13(19-20):875-81. PubMed ID: 18639646
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ATP-noncompetitive inhibitors of CDK-cyclin complexes.
    Orzáez M; Gortat A; Mondragón L; Bachs O; Pérez-Payá E
    ChemMedChem; 2009 Jan; 4(1):19-24. PubMed ID: 19039815
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Coming full circle: cyclin-dependent kinases as anti-cancer drug targets.
    Fisher RP
    Subcell Biochem; 2010; 50():1-15. PubMed ID: 20012574
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclin-dependent kinase inhibitors: a survey of recent patent literature.
    Galons H; Oumata N; Meijer L
    Expert Opin Ther Pat; 2010 Mar; 20(3):377-404. PubMed ID: 20180621
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclin-dependent kinase modulators: a novel class of cell cycle regulators for cancer therapy.
    Senderowicz AM
    Cancer Chemother Biol Response Modif; 2001; 19():165-88. PubMed ID: 11686013
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel potent pharmacological cyclin-dependent kinase inhibitors.
    Węsierska-Gądek J; Chamrád I; Kryštof V
    Future Med Chem; 2009 Dec; 1(9):1561-81. PubMed ID: 21425979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclins and related kinases in cancer cells.
    Malumbres M
    J BUON; 2007 Sep; 12 Suppl 1():S45-52. PubMed ID: 17935277
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent advances and new directions in the discovery and development of cyclin-dependent kinase inhibitors.
    Fischer PM
    Curr Opin Drug Discov Devel; 2001 Sep; 4(5):623-34. PubMed ID: 12825457
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Development of new antitumor reagents which block the cell cycle progression].
    Osada H
    Gan To Kagaku Ryoho; 1997 Sep; 24(11):1541-6. PubMed ID: 9309153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CDK inhibitors in cancer therapy: what is next?
    Malumbres M; Pevarello P; Barbacid M; Bischoff JR
    Trends Pharmacol Sci; 2008 Jan; 29(1):16-21. PubMed ID: 18054800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure-based discovery and optimization of potential cancer therapeutics targeting the cell cycle.
    Thomas MP; McInnes C
    IDrugs; 2006 Apr; 9(4):273-8. PubMed ID: 16596481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SNS-032 is a potent and selective CDK 2, 7 and 9 inhibitor that drives target modulation in patient samples.
    Conroy A; Stockett DE; Walker D; Arkin MR; Hoch U; Fox JA; Hawtin RE
    Cancer Chemother Pharmacol; 2009 Sep; 64(4):723-32. PubMed ID: 19169685
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclin-dependent kinases as targets for cancer therapy.
    Senderowicz AM
    Cancer Chemother Biol Response Modif; 2002; 20():169-96. PubMed ID: 12703205
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting Cyclin-Dependent Kinases and Cell Cycle Progression in Human Cancers.
    Santo L; Siu KT; Raje N
    Semin Oncol; 2015 Dec; 42(6):788-800. PubMed ID: 26615126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Chemical inhibitors of cyclic-dependent kinases: preclinical and clinical study].
    Damiens E; Meijer L
    Pathol Biol (Paris); 2000 Apr; 48(3):340-51. PubMed ID: 10858966
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis, and evaluation of 3,4-disubstituted pyrazole analogues as anti-tumor CDK inhibitors.
    Lin R; Chiu G; Yu Y; Connolly PJ; Li S; Lu Y; Adams M; Fuentes-Pesquera AR; Emanuel SL; Greenberger LM
    Bioorg Med Chem Lett; 2007 Aug; 17(16):4557-61. PubMed ID: 17574416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CDK/GSK-3 inhibitors as a new approach for the treatment of proliferative renal diseases.
    Soos TJ; Meijer L; Nelson PJ
    Drug News Perspect; 2006; 19(6):325-8. PubMed ID: 16971968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclin-dependent kinase inhibitors for the treatment of chronic lymphocytic leukemia.
    Blachly JS; Byrd JC; Grever M
    Semin Oncol; 2016 Apr; 43(2):265-73. PubMed ID: 27040705
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Small molecules as inhibitors of cyclin-dependent kinases.
    Huwe A; Mazitschek R; Giannis A
    Angew Chem Int Ed Engl; 2003 May; 42(19):2122-38. PubMed ID: 12761741
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclin-Dependent Kinase Inhibitors as Anticancer Therapeutics.
    Law ME; Corsino PE; Narayan S; Law BK
    Mol Pharmacol; 2015 Nov; 88(5):846-52. PubMed ID: 26018905
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.